---
title: "Guo 2025 — Exploring the Causal Associations of the Gut Microbiota and Plasma Metabolites with Ovarian Cancer"
type: source
created: 2026-04-09
updated: 2026-04-17
authors: [Jia Guo, Cheng Wang, Hui Li, Chunfang Ding]
institution: "not yet verified"
journal: "Journal of Ovarian Research"
year: 2025
doi: "10.1186/s13048-025-01610-9"
tags: [ovarian-cancer, Mendelian-randomization, gut-microbiota, plasma-metabolites, Dialister, Bifidobacterium-bifidum, network-pharmacology, butyrate]
platform: both
condition: "ovarian cancer"
evidence_level: computational-prediction
sample_size: "N/A"
taxa_discussed: [bifidobacterium, dialister]
metals_discussed: []
karen_brain_primitives: [3, 5]
key_findings:
  - "Seven risk-factor and five protective gut microbes causally associated with OC"
  - "Caffeic acid, sphingomyelin, and ceramide metabolites identified as OC risk factors"
  - "Phenylalanine and butyric acid metabolites were protective against OC"
keystone: false
---

## Key Findings

- **Seven risk-factor gut microbes and five protective gut microbes** were causally associated with ovarian cancer risk through two-sample Mendelian randomization ([[guo-2025-causal-gut-microbiota-metabolites-ovarian-cancer-mr|this study]], computational-prediction).
- **Caffeic acid, sphingomyelin, and ceramide metabolites** were identified as causal risk factors for OC, implicating lipid and phenolic acid metabolism in ovarian carcinogenesis.
- **Phenylalanine and butyric acid metabolites** were protective against OC, consistent with the known anti-inflammatory and anti-proliferative properties of short-chain fatty acids.
- **Network pharmacology and molecular docking** were used to validate the biological plausibility of the identified metabolite-OC associations.
- **[[Bifidobacterium]]** species were among the protective taxa, while **[[Dialister]]** appeared among the risk-associated genera.

## Methods

- **Study type**: Two-sample Mendelian randomization with network pharmacology and molecular docking validation.
- **Microbiome GWAS data**: MiBioGen consortium (n=18,340) and Dutch Microbiome Project (n=7,738).
- **Metabolite GWAS data**: Approximately 1,400 plasma metabolites from large-scale GWAS.
- **Outcome data**: Ovarian Cancer Association Consortium (OCAC, 25,509 OC cases).
- **MR approaches**: Standard two-sample MR methods with sensitivity analyses for pleiotropy and instrument strength.
- **Validation**: Network pharmacology analysis identifying shared targets between metabolites and OC pathways; molecular docking to assess metabolite-target protein binding affinities.

## Detailed Summary

This study uses genetic epidemiology to infer causal relationships between gut microbiota, circulating metabolites, and ovarian cancer risk. The combination of Mendelian randomization with network pharmacology is a methodological strength, as it moves beyond statistical association to biological plausibility.

The identification of butyric acid metabolites as protective is biologically coherent. Butyrate, the primary short-chain fatty acid produced by gut microbial fermentation of dietary fiber, has well-documented anti-cancer properties including histone deacetylase (HDAC) inhibition, anti-inflammatory signaling, and promotion of colonic epithelial integrity. The finding that Bifidobacterium — a major producer of acetate that cross-feeds butyrate producers — is protective aligns with this metabolic framework.

The risk-factor metabolites (caffeic acid, sphingomyelin, ceramide) are more complex to interpret. Sphingomyelin and ceramide are bioactive lipids involved in cell signaling, apoptosis, and inflammation. Elevated circulating ceramides have been associated with chronic inflammatory states. Caffeic acid is a phenolic compound found in many foods and also produced by microbial metabolism; its identification as a risk factor is unexpected given its known antioxidant properties and may reflect complex dose-response or context-dependent effects.

The presence of Dialister as a risk-associated genus is notable because this taxon has appeared in multiple MR studies of gynecological conditions, suggesting a pattern worth tracking across ovarian, endometrial, and cervical cancer signatures.

## Relevance to WikiBiome

- Informs [[bifidobacterium]] entity page with genetic evidence for a protective role against ovarian cancer.
- Relevant to [[dialister]] entity page as a risk-associated taxon for OC.
- Supports [[butyrate]] concept/entity page with evidence connecting butyrate metabolism to cancer protection.
- Relevant to [[ferroptosis]] through lipid (ceramide/sphingomyelin) metabolite connections to cell death pathways.

## Relevance to Cureva

- The protective role of butyrate-associated metabolites supports fiber-rich dietary interventions and SCFA-producing probiotic strategies for OC risk reduction.
- The risk metabolites (ceramides, sphingomyelins) could serve as monitoring biomarkers.
- Network pharmacology targets may identify drug repurposing opportunities for OC prevention.

## Open Questions

- Whether the caffeic acid risk association is direct or reflects confounding through dietary patterns or microbial metabolism.
- How metal status (particularly iron and zinc) influences the abundance of protective vs. risk-associated gut microbes in OC.
- Whether the Dialister risk association replicates across independent MR analyses and in other gynecological cancers.
- The specific Bifidobacterium species and strains responsible for the protective effect.
